Valuation: Nexstim Plc

Market Cap 78.73M 90.86M 74.3M 67.4M 126M 8.71B 127M 887M 342M 4.42B 341M 334M 14.04B P/E 2026 *
97.5x
P/E 2027 * 42.4x
Enterprise Value 77.08M 88.96M 72.74M 65.99M 124M 8.53B 125M 869M 335M 4.33B 334M 327M 13.75B EV / Sales 2026 *
5.8x
EV / Sales 2027 * 4.88x
Free-Float
59.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-0.86% - - 90.86M
+0.62%-0.03%+27.98%+19.00% 227B
+1.55%-2.12%+6.95%-19.82% 143B
+2.38%+3.07%-15.95%+24.43% 134B
+4.82%-5.75%-56.14%-14.87% 65.29B
-0.82%-0.59%-18.91%-15.95% 50.09B
+1.36%-4.87%+10.25%+15.54% 49.29B
-0.09%-2.69%+19.12%+27.79% 41.39B
+0.41%+0.15%+38.80%+50.73% 40.28B
+2.16%-2.35%-17.45%+51.04% 31.9B
Average +1.13%-1.73%-0.60%+15.32% 86.84B
Weighted average by Cap. +1.41%-0.91%+3.71%+10.95%

Financials

2026 *2027 *
Net sales 13.3M 15.35M 12.55M 11.39M 21.36M 1.47B 21.51M 150M 57.76M 746M 57.65M 56.38M 2.37B 15.55M 17.95M 14.67M 13.31M 24.97M 1.72B 25.15M 175M 67.53M 873M 67.4M 65.92M 2.77B
Net income 750K 866K 708K 642K 1.2M 82.96M 1.21M 8.45M 3.26M 42.09M 3.25M 3.18M 134M 1.85M 2.14M 1.75M 1.58M 2.97M 205M 2.99M 20.85M 8.03M 104M 8.02M 7.84M 330M
Net Debt -1.65M -1.9M -1.56M -1.41M -2.65M -183M -2.67M -18.6M -7.17M -92.59M -7.15M -6.99M -294M -2.8M -3.23M -2.64M -2.4M -4.5M -310M -4.53M -31.56M -12.16M -157M -12.14M -11.87M -500M
Logo Nexstim Plc
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!